www.idosr.org
©IDOSR PUBLICATIONS
Twesigwe, 2025
ISSN: 2550-7931
International Digital Organization for Scientific Research
IDOSR JOURNAL OF APPLIED SCIENCES 10(2):95-100, 2025.
https://doi.org/10.59298/IDOSRJAS/2025/102.95100
IDOSRJAS1020000

Targeting the Plasmodium Lifecycle: Advances and Challenges in Antimalarial Drug Development

Twesigye Davis

Department of Pharmacognosy Kampala International University Uganda
Email: twesigyedavis@studwc.kiu.ac.ug

ABSTRACT

Malaria remains one of the world's most devastating infectious diseases, caused by Plasmodium parasites transmitted through Anopheles mosquitoes. Despite global efforts to reduce its burden, resistance to existing antimalarial drugs threatens to reverse progress, prompting the need for novel therapeutic strategies. Targeting the complex Plasmodium lifecycle-spanning the liver, blood, and mosquito stages-offers multiple intervention points. This review explores recent advances in antimalarial drug development with a focus on lifecycle-specific targets. Key breakthroughs include new endoperoxides, mitochondrial inhibitors, and transmission-blocking agents. Additionally, emerging platforms such as proteomic screening, CRISPR-Cas9 gene editing, and structure-based drug design have accelerated the identification of promising compounds. However, challenges such as drug resistance, toxicity, limited efficacy across all lifecycle stages, and translational hurdles from bench to bedside persist. A multipronged approach, combining stage-specific therapies, host-targeted interventions, and strategic drug combinations, is critical for sustainable malaria control and eventual eradication.

Keywords: Plasmodium lifecycle, antimalarial drug development, drug resistance, transmission-blocking agents, liver-stage therapeutics

INTRODUCTION

Malaria remains a significant public health burden, particularly in tropical and subtropical regions, where it contributes to high morbidity and mortality rates [1]. The disease is primarily caused by Plasmodium falciparum and Plasmodium vivax, two of the five known Plasmodium species that infect humans. Among these, P. falciparum accounts for the majority of severe disease cases and fatalities, especially in sub-Saharan Africa, while P. vivax is more geographically widespread and capable of forming dormant liver-stage hypnozoites that lead to relapse [2]. Globally, over 240 million malaria cases and an estimated 600,000 deaths occur each year, according to World Health Organization reports [3]. Efforts to combat malaria have made significant strides over the past two decades, driven by the widespread use of insecticide-treated bed nets, indoor residual spraying, improved diagnostic tools, and more effective drug therapies. Artemisinin-based combination therapies (ACTs) are currently the first-line treatment for uncomplicated P. falciparum malaria [4]. These therapies combine fast-acting artemisinin derivatives with longer-lasting partner drugs, which together improve treatment outcomes and reduce the risk of resistance development [5]. However, the emergence of artemisinin resistance in parts of Southeast Asia and, more recently, East Africa poses a serious threat to global malaria control and eradication efforts [6]. Resistance is characterized by delayed parasite clearance and reduced sensitivity to artemisinin and its partner drugs, leading to an increased risk of treatment failure [7]. This situation underscores the urgent need for new antimalarial drugs with novel mechanisms of action. One promising strategy involves targeting different stages of the Plasmodium lifecycle. The parasite undergoes a complex development process involving multiple morphological forms across both human and mosquito hosts. These include the liver stage (pre-erythrocytic), the asexual blood stage (which causes disease symptoms), and the sexual and mosquito stages (which facilitate transmission) [8]. Each stage presents unique biological characteristics and vulnerabilities that can be exploited through targeted drug development. Focusing on stage-specific drug targets allows researchers to design compounds that are not only curative but also preventive and transmission-blocking. Drugs that target the liver stage can prevent the onset of blood-stage infection and symptoms, while those targeting gametocytes or mosquito-stage forms can halt the cycle of transmission [9]. This

lifecycle-based approach enhances the potential for more effective, comprehensive, and sustainable malaria control strategies.

2. The Plasmodium Lifecycle: Opportunities for Intervention

The Plasmodium lifecycle is complex, involving multiple developmental stages in both human and mosquito hosts. Each stage offers unique targets for therapeutic intervention.

2.1 Liver (Pre-erythrocytic) Stage

After a bite from an infected mosquito, Plasmodium sporozoites enter the human bloodstream and rapidly migrate to the liver [10]. Here, they invade hepatocytes and undergo asexual replication over 7 to 14 days, producing thousands of merozoites [10]. This liver stage is clinically silent but crucial, as it seeds the symptomatic blood-stage infection. Targeting this stage offers opportunities for prophylactic or causal preventive treatment [11]. Currently, only a few drugs such as atovaquone and primaquine exhibit liver-stage activity [12]. Primaquine is particularly effective against P. vivax hypnozoites but poses risks of hemolysis in individuals with G6PD deficiency [13]. To address the limitations of existing treatments, new liver-stage targeted compounds are under development. These include imidazolopiperazines like KAF156, which show activity against both liver and blood stages, and phosphatidylinositol 4-kinase (PI4K) inhibitors like MMV390048, which demonstrate multi-stage potency and are progressing through clinical trials [14].

2.2 Asexual Blood Stage

The blood stage is responsible for the clinical manifestations of malaria, including fever, anemia, and, in severe cases, cerebral complications and death [15]. This stage has been the primary focus of most antimalarial drug development efforts. Merozoites released from the liver invade red blood cells, undergo multiple rounds of replication, and continue the cycle [16]. Artemisinin and its derivatives are the most effective blood-stage drugs, but resistance has necessitated the development of novel alternatives. One promising class includes synthetic ozonides such as OZ439 (artefenomel), which mimic the peroxide bond of artemisinin while offering a longer half-life and once-daily dosing [17]. Other advances include mitochondrial electron transport inhibitors like DSM265, which target dihydroorotate dehydrogenase (DHODH) and offer a unique mechanism of action distinct from existing therapies [18].

2.3 Sexual and Mosquito Stages

During the blood-stage infection, some parasites differentiate into sexual forms known as gametocytes, which are taken up by mosquitoes during a blood meal [19]. These gametocytes mature into male and female gametes in the mosquito midgut, leading to fertilization and development into sporozoites that can infect another human host [20]. Interrupting this transmission cycle is a key component of malaria eradication strategies. Drugs that target gametocytes, zygotes, or ookinetes can block parasite development in mosquitoes, thereby reducing the reservoir of infection. Tafenoquine, a derivative of primaquine, has shown gametocytocidal activity and is used for both radical cure and transmission-blocking [21]. Other compounds under development aim to target these later stages, offering promise for integrated malaria control.

3. Recent Advances in Drug Discovery Platforms

Innovations in drug discovery tools and platforms have greatly accelerated the identification and optimization of new antimalarial compounds.

3.1 High-throughput Screening and Chemoproteomics

Modern drug discovery has benefited from high-throughput screening (HTS) technologies, which allow researchers to test thousands of compounds for antimalarial activity in a relatively short time. Both phenotypic screens (which assess overall parasite viability) and target-based screens (which focus on specific enzymes or pathways) have led to the discovery of novel chemical scaffolds [22,23,24]. Initiatives like the Malaria Box and Pathogen Box by Medicines for Malaria Venture (MMV) have made libraries of active compounds freely available to the global research community [25].

3.2 Structural Biology and In Silico Modeling

Advances in structural biology, including high-resolution X-ray crystallography and cryo-electron microscopy, have revealed the detailed architecture of critical Plasmodium proteins [26]. This information enables structure-guided drug design, allowing for the rational development of inhibitors that precisely fit target binding sites. Additionally, in silico modeling and machine learning algorithms are being used to predict binding affinities and optimize lead compounds for better efficacy and safety profiles [27].

3.3 CRISPR-Cas9 and Reverse Genetics

The application of CRISPR-Cas9 gene-editing technology in Plasmodium research has opened new avenues for functional genomics. Researchers can now knock out or modify specific genes to determine their role in parasite survival, development, and drug susceptibility [28]. This has accelerated the validation of drug targets, particularly for essential genes involved in liver and sexual stages. Reverse genetics approaches are also helping to identify compensatory pathways that may contribute to drug resistance [29].

4. Challenges in Antimalarial Drug Development

Despite decades of progress in malaria control, the development of new antimalarial drugs continues to face several formidable challenges. These issues hinder the effectiveness, deployment, and long-term sustainability of pharmacological interventions.

4.1 Drug Resistance

The evolution of drug-resistant *Plasmodium* strains remains one of the greatest threats to malaria control and eradication [30]. Resistance typically arises from genetic mutations in parasite enzymes targeted by drugs. For example, mutations in the Kelch13 gene are associated with artemisinin resistance, leading to delayed parasite clearance in treated individuals [31]. Similarly, resistance to older drugs like chloroquine and sulfadoxine-pyrimethamine emerged due to mutations in transporter and folate pathway genes [32]. In some cases, the parasite upregulates efflux pumps, reducing intracellular drug accumulation [33]. Combating resistance requires ongoing surveillance to detect emerging mutations, as well as the development of novel compounds with different mechanisms of action that can bypass or delay resistance development.

4.2 Limited Stage-specific Efficacy

Most currently approved antimalarials are primarily effective against the asexual blood stage of the parasite lifecycle, which is responsible for the symptoms of the disease [34]. However, these agents do little to eliminate parasites in the liver or in sexual stages like gametocytes, which are crucial for transmission [34]. As a result, individuals may continue to serve as reservoirs of infection or experience relapses, especially in *P. vivax* infections. Multi-stage active drugs or rational drug combinations targeting several lifecycle stages simultaneously are essential to achieve full parasite clearance, prevent transmission, and avoid recrudescence. Developing such agents, however, remains technically demanding and expensive.

4.3 Toxicity and Safety

Safety is a critical consideration in antimalarial drug development, particularly for treatments used in mass drug administration or in vulnerable populations such as children and pregnant women. Some effective compounds, such as primaquine and tafenoquine, can cause hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is common in malaria-endemic regions [35]. Others may carry hepatotoxicity risks or have poor safety margins at therapeutic doses. Long drug half-lives, although beneficial for reducing dosing frequency, can also increase the risk of drug accumulation and adverse effects [36]. Therefore, comprehensive preclinical safety testing and pharmacovigilance are essential components of drug development and public health deployment.

4.4 Translation and Implementation Gaps

A major obstacle to antimalarial innovation is the difficulty in translating laboratory findings into clinically viable therapies. Many promising compounds fail in advanced preclinical or early clinical stages due to poor pharmacokinetics, toxicity, or limited efficacy in vivo [37]. Moreover, clinical trials in malaria-endemic areas require robust infrastructure, trained personnel, and community engagement, all of which may be lacking in resource-limited settings. In addition, regulatory hurdles, inconsistent funding, and inadequate partnerships between academic, governmental, and commercial stakeholders can delay the development and adoption of new treatments. Addressing these barriers requires a coordinated effort that includes investment in local research capacity and global health collaboration.

5. Future Directions and Integrated Approaches

The future of antimalarial drug development will rely on multidisciplinary, integrated strategies that address current limitations while advancing innovative solutions. One priority is the development of **triple-drug therapies** that combine three antimalarial agents with complementary mechanisms of action. This approach aims to enhance efficacy and delay the onset of resistance by reducing the parasite's ability to adapt to multiple drugs simultaneously. In parallel, **vaccines and immunomodulators** are being explored to complement pharmacological interventions. Although the RTS,S/AS01 malaria vaccine has shown partial efficacy, next-generation candidates and immune-enhancing agents may offer improved protection, especially when integrated with drug-based strategies. Another promising area involves **host-targeted therapies**, which disrupt parasite-host interactions essential for parasite survival and replication. By targeting host enzymes or immune pathways, these treatments may exert pressure on the parasite without promoting resistance as directly as pathogen-targeted drugs. Finally, the **One Health and ecological approach** recognizes that malaria transmission is influenced not only by human and parasite factors but

also by environmental and vector dynamics. Integrated vector management, improved housing, sanitation, and climate adaptation strategies must be incorporated alongside drug development to achieve sustained malaria control. Public-private partnerships, such as Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and the Bill & Melinda Gates Foundation, play a critical role in bridging innovation and implementation. These collaborations help fund research, accelerate clinical trials, support regulatory approvals, and ensure equitable access to life-saving treatments in low-income countries. Together, these future-focused efforts promise to reshape the global antimalarial landscape and move closer toward the goal of malaria elimination and eradication.

CONCLUSION

A comprehensive understanding of the Plasmodium lifecycle enables the rational design of next-generation antimalarial drugs. While significant progress has been made, persistent challenges necessitate continued innovation, collaboration, and investment. A combination of lifecycle-targeted therapeutics, improved diagnostic tools, and integrated public health strategies is essential to achieving the ultimate goal of malaria eradication.

REFERENCES

1. Zewale TA, Wondmagegn LY, Getahun HA, Tariku MK, Achamyeleh AA, Asemahagn MA, et al. Trends of malaria incidence, prevalence, mortality, and disability-adjusted life years in Eastern Africa region from 1990 to 2021: a systematic analysis from Global Burden of Disease 2021 study. PubMed. 2025;24(1):207. Available from: https://pubmed.ncbi.nlm.nih.gov/40598172/
2. Alum EU, Ugwu OPC, Egba SI, Uti DE, Alum BN. Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research 2024; 11(2):16-22. https://doi.org/10.59298/INOSRSR/2024/1.1.21622
3. World malaria report 2024. 2024. Available from: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024
4. Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu, Simeon Ikechukwu Egba and Obioma Raluchukwu Emeka Obi. Combatting Anaemia in Paediatric Malaria: Effective management strategies Int. J. Curr. Res. Med. Sci. 2023. 9(11): 1-7
5. Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? The Lancet Infectious Diseases. 2024;24(9):e591–600. doi:10.1016/S1473-3099(24)00141-5
6. Van Der Pluijm RW, Amaratunga C, Dhorda M, Dondorp AM. Triple artemisinin-based combination therapies for malaria – a new paradigm? Trends in Parasitology. 2020;37(1):15–24. doi:10.1016/J.PT.2020.09.011
7. Obeagu, E. I., Alum, E. U. and Ugwu, O. P. C. Hepcidin: The Gatekeeper of Iron in Malaria Resistance NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. 2023; 4(2):1-8. https://doi.org/10.59298/NIJRMS/2023/10.1.1400
8. Zekar L, Sharman T. Plasmodium falciparum malaria. StatPearls – NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555962/
9. Birkholtz LM, Alano P, Leroy D. Transmission-blocking drugs for malaria elimination. Trends in Parasitology. 2022;38(5):390–403. doi:10.1016/J.PT.2022.01.011
10. Kungu, E., Inyangat, R., Ugwu, O.P.C. and Alum, E. U. Exploration of Medicinal Plants Used in the Management of Malaria in Uganda. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES 2023; 4(1):101-108.https://nijournals.org/wp-content/uploads/2023/10/NIJRMS-41101-108-2023.docx.pdf
11. Kaushansky A, Minkah N. Liver-stage Plasmodium infection tunes clinical outcomes. Trends in Parasitology. 2023;39(5):321–2. doi:10.1016/J.PT.2023.03.004
12. Derbyshire ER, Mota MM, Clardy J. The next opportunity in anti-malaria drug discovery: the liver stage. PLoS Pathogens. 2011;7(9):e1002178. doi:10.1371/JOURNAL.PPAT.1002178
13. Avalos S, Mejia RE, Banegas E, Salinas C, Gutierrez L, Fajardo M, et al. G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients. Malaria Journal. 2018;17(1). doi:10.1186/S12936-018-2564-2
14. LaMonte GM, Rocamora F, Marapana DS, Gnädig NF, Ottilie S, Luth MR, et al. Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. Nature Communications. 2020;11(1). doi:10.1038/S41467-020-15440-4
15. Emmanuel Ikechukwu Nnamonu., Ogonna Christiana Ani., Felix Joel Ugwu., Simeon Ikechukwu Egba., Ifeanyi Oscar Aguzie., Obiageli Panthe Okeke., Christian Enyi Dialoke., Lilian Obinna Asogwa and Solomon Ikechukwu Odo. Malaria Prevalence in Rice Farm Settlements South East Nigeria. *IJTDH*, 2020; 41(9): 64-74

16. Vaughan AM, Kappe SHI. Malaria parasite liver infection and exoerythrocytic biology. Cold Spring Harbor Perspectives in Medicine. 2017;7(6):a025486. doi:10.1101/CSHPERSPECT.A025486
17. Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. The Lancet Infectious Diseases. 2015;16(1):61–9. doi:10.1016/S1473-3099(15)00320-5
18. Siqueira-Neto JL, Wicht KJ, Chibale K, Burrows JN, Fidock DA, Winzeler EA. Antimalarial drug discovery: progress and approaches. Nature Reviews Drug Discovery. 2023;22(10):807–26. doi:10.1038/S41573-023-00772-9
19. Venugopal K, Hentzschel F, Valkiūnas G, Marti M. Plasmodium asexual growth and sexual development in the haematopoietic niche of the host. Nature Reviews Microbiology. 2020;18(3):177–89. doi:10.1038/S41579-019-0306-2
20. Obeagu, E. I., **Alum, E. U.** and Ugwu, O. P. C. Hepcidin's Antimalarial Arsenal: Safeguarding the Host. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY. 2023; 4(2):1-8. https://doi.org/10.59298/NIJPP/2023/10.1.1100
21. Chu CS, Freedman DO. Tafenoquine and G6PD: a primer for clinicians. Journal of Travel Medicine. 2019. doi:10.1093/JTM/TAZ023
22. Hovlid ML, Winzeler EA. Phenotypic screens in antimalarial drug discovery. Trends in Parasitology. 2016;32(9):697–707. doi:10.1016/J.PT.2016.04.014
23. Guerra F, Winzeler EA. New targets for antimalarial drug discovery. Current Opinion in Microbiology. 2022;70:102220. doi:10.1016/J.MIB.2022.102220
24. Borsari C, Ferrari S, Venturelli A, Costi MP. Target-based approaches for the discovery of new antimycobacterial drugs. Drug Discovery Today. 2016;22(3):576–84. doi:10.1016/J.DRUDIS.2016.11.014
25. Samby K, Willis PA, Burrows JN, Laleu B, Webborn PJH. Actives from MMV Open Access Boxes? A suggested way forward. PLoS Pathogens. 2021;17(4):e1009384. doi:10.1371/JOURNAL.PPAT.1009384
26. Wong W, Bai XC, Brown A, Fernandez IS, Hanssen E, Condron M, et al. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine. eLife. 2014;3. doi:10.7554/ELIFE.03080
27. Chang Y, Hawkins BA, Du JJ, Groundwater PW, Hibbs DE, Lai F. A guide to in silico drug design. Pharmaceutics. 2022;15(1):49. doi:10.3390/PHARMACEUTICS15010049
28. Nourani L, Mehrizi AA, Pirahmadi S, Pourhashem Z, Asadollahi E, Jahangiri B. CRISPR/Cas advancements for genome editing, diagnosis, therapeutics, and vaccine development for Plasmodium parasites, and genetic engineering of Anopheles mosquito vector. Infection Genetics and Evolution. 2023;109:105419. doi:10.1016/J.MEEGID.2023.105419
29. Zheng XS, Chan TF, Zhou HH. Genetic and genomic approaches to identify and study the targets of bioactive small molecules. Chemistry & Biology. 2004;11(5):609–18. doi:10.1016/J.CHEMBIOL.2003.08.011
30. Ippolito MM, Moser KA, Kabuya JBB, Cunningham C, Juliano JJ. Antimalarial drug resistance and implications for the WHO Global Technical Strategy. Current Epidemiology Reports. 2021;8(2):46–62. doi:10.1007/S40471-021-00266-5
31. Abubakar UF, Adam R, Mukhtar MM, Muhammad A, Yahuza AA, Ibrahim SS. Identification of mutations in antimalarial resistance gene Kelch13 from Plasmodium falciparum isolates in Kano, Nigeria. Tropical Medicine and Infectious Disease. 2020;5(2):85. doi:10.3390/TROPICALMED5020085
32. Wicht KJ, Mok S, Fidock DA. Molecular mechanisms of drug resistance in Plasmodium falciparum malaria. Annual Review of Microbiology. 2020;74(1):431–54. doi:10.1146/ANNUREV-MICRO-020518-115546
33. Kabra R, Chauhan N, Kumar A, Ingale P, Singh S. Efflux pumps and antimicrobial resistance: paradoxical components in systems genomics. Progress in Biophysics and Molecular Biology. 2018;141:15–24. doi:10.1016/J.PBIOMOLBIO.2018.07.008
34. Shibeshi MA, Kifle ZD, Atnafie SA. Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infection and Drug Resistance. 2020;13:4047–60. doi:10.2147/IDR.S279433
35. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Neglected Tropical Diseases. 2018;12(4):e0006230. doi:10.1371/JOURNAL.PNTD.0006230
36. Hallare J, Gerriets V. Elimination half-life of drugs. StatPearls – NCBI Bookshelf. 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554498/

37. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B. 2022;12(7):3049–62. doi:10.1016/J.APSB.2022.02.002

CITE AS: Twesigye Davis (2025). Targeting the Plasmodium Lifecycle: Advances and Challenges in Antimalarial Drug Development IDOSR JOURNAL OF APPLIED SCIENCES 10(2):95-100, 2025. https://doi.org/10.59298/IDOSRJAS/2025/102.95100